Maria Alessandra Calegari

7PUBLICATIONS
49CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 22, 2026
On-Treatment Grade 3-4 Neutropenia and Clinical Outcomes with Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: ReTrITA Real-World Evidence.

|Oct 29, 2025
Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study.

Carlo Signorelli, Michele Basso, Maria Alessandra Calegari

|Dec 27, 2024
Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study.

Carlo Signorelli, Maria Alessandra Calegari, Annunziato Anghelone

|Jan 05, 2024
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study.

Carmine Pinto, Armando Orlandi, Nicola Normanno

|Mar 08, 2022
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.

Federica Morano, Alessandra Raimondi, Filippo Pagani

|Nov 14, 2019
PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target.

Lisa Salvatore, Maria Alessandra Calegari, Fotios Loupakis

Pageof 2

Frequent Collaborators

3 joint publications

Alessandro Bittoni

3 joint publications

Fiorenza Santamaria

3 joint publications

Ina Valeria Zurlo

3 joint publications

Alessandro Passardi